Formulary e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.
|
to Formulary e-News
|
|
 |
|
 |
Survey
This month we would like to know...
With the recent announcement of Medco's acquisition by Express Scripts, potentially bringing 2 of the nation's largest PBMs together, what do you see as the most significant implications of such consolidation for the industry?
a) Enhanced competition within the industry, inevitably translating to even lower drug costs for PBM payer clients.
b) Unfair advantages for Express Scripts based upon its size, thus reducing competition and potentially increasing long-term costs for payers.
c) Increased pressures on retail pharmacies forcing more pharmacies out of business.
d) Increased quality of PBM clinical, analytic and administrative services across the industry, as other PBMs strive to stay competitive.
e) Minimal, if any, impact.
|
|
|
FDA has notified healthcare professionals that the Boxed Warning for the entire class of tumor necrosis factor-alpha (TNF-alpha) blockers has been updated to include the risk of infection from 2 bacterial pathogens, Legionella and Listeria. Read full article. |
 |
An FDA advisory panel voted 9-2 (with 1 abstention) to recommend approval for rivaroxaban (Xarelto, Johnson & Johnson and Bayer AG), an oral, once-daily anticoagulant, as a treatment to prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Read full article. |
|
|
Colchicine is a safe and effective treatment for patients who have had a first recurrence of pericarditis, according to a recent study published August 28, in the Annals of Internal Medicine. Read full article.
|
|
An antimicrobial lock solution containing minocycline in combination with EDTA (M-EDTA) reduces the rate of catheter-related bacteremia (CRB) in hemodialysis patients, according to the results of a study published online in the Journal of the American Society of Nephrology. Read full article.
|
|
FDA issued a complete response letter (CRL) for a golimumab (Simponi, Janssen Biotech) supplemental Biologics License Application (sBLA) seeking an expanded label in the treatment of active psoriatic arthritis. Read full article.
|
|
|
|
|
|
Contact Us |
Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
 Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
